0
Lung Cancer: Lung Cancer III |

Assessing Utility of Blood-Based Predictive and Prognostic Proteomic Test in Patient Non-small Cell Lung Cancer

Valentine Ifeacho, MD; Prathamesh Prabhudesai, MD; Viola Zhu, MD; Daya Upadhyay, MD
Author and Funding Information

University of California San Francisco, Fresno, CA


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):725A. doi:10.1016/j.chest.2016.08.820
Text Size: A A A
Published online

Extract

SESSION TITLE: Lung Cancer III

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Lung cancer is the most common cancer worldwide, and is the leading cancer killer in both men and women in the United States. The overall five-year survival rate for lung cancer continues to remain poor <18 percent. Therefore, there is a need for predictive biomarker tests that can identify which therapies are most appropriate for individual patients and assess their prognostic outcome. A Blood/Serum-based proteomic test veristrat by mass spectrometry has been used to predict outcomes of patients with non-small cell lung cancer (NSCLC). The test classifies the patients in the poor group have worse outcomes after treatment as compared to patients with the good group which respond to treatment. Although this test was initially developed for patients with EGFR mutation, given that the majority of NSCLC cases do not harbor activating mutations in the EGFR gene, utility of this test must be assessed in all patients with NSCLC. In this study, we examined the predictive and prognostic values of blood-based proteomic test in assessing disease progression and recurrence in lung cancer.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543